Area of research
Molecular Biology · Oncology
Research interest
Research focused on KRAS and PD-L1, with related work in Diabetic nephropathy, Erlotinib, Pancreatic cancer. Notable publications include 'Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised,...', 'Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer', and 'PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis'.
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
LINC00323 mediates the role of M1 macrophage polarization in diabetic nephropathy through PI3K/AKT signaling pathway
PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial
Elevated Levels of Serum β2-Glycoprotein I/Oxidized Low-Density Lipoprotein Complexes Are Associated with Cerebral Infarction in Patients with Type 2 Diabetes Mellitus